Key result
Propranolol plus flecainide suppresses refractory pleomorphic VT and reverses cardiomyopathy in SLC29A3-associated disease.
Case Report (n=1)
This case report describes the first known presentation of reversible arrhythmia-induced cardiomyopathy secondary to recurrent non-sustained pleomorphic ventricular tachycardia in a patient with an SLC29A3-related multisystemic disorder, successfully treated with propranolol and flecainide.
Hypothesis-generating for ventricular arrhythmias in SLC29A3 disorders; prospective studies needed to guide evaluation.
We present a 16-year-old female with multisystemic disorder characterized by cutaneous hyperpigmentation, hypertrichosis, hepatosplenomegaly, hearing loss, heart anomalies, hypogonadism, low height (short stature), hyperglycemia and hallux valgus and pathogenic variant in SLC29A3 gene (encoding the human equilibrate nucleoside transporter (hENT3), was referred for evaluation due to recurrent non-sustained pleomorphic ventricular tachycardia refractory to amiodarone and catheter ablation. Two-dimensional echocardiography and cardiac magnetic resonance with late-gadolinium enhancement showed reduced biventricular ejection fraction without signs of inflammation or fibrosis. The administration of propranolol and flecainide controlled her ventricular arrhythmias and improved ventricular function. To our knowledge, this the first time that this arrhythmic phenotype has been demonstrated in this unusual syndrome presenting probably as a cardiomyopathy secondary to recurrent non-sustained pleomorphic ventricular tachycardia that was reversed with administration of flecainide and propranolol.
No takes yet. Share an insight, caveat, or question.
Pellizzón et al. (2026) conducted a case report in Reversible cardiomyopathy secondary to recurrent non-sustained pleomorphic ventricular tachycardia in a multisystemic disorder with pathogenic SLC29A3 variant (n=1). Propranolol and flecainide was evaluated on Control of ventricular arrhythmias and improvement in ventricular function. Propranolol and flecainide controlled refractory pleomorphic ventricular tachycardia and reversed cardiomyopathy in a 16-year-old female with a pathogenic SLC29A3 variant (n=1).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: